Liquidia (NASDAQ:LQDA) Director Sells $6,388,491.01 in Stock

Posted by Brenda Bartman on Oct 10th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Stephen Bloch sold 235,477 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $27.13, for a total value of $6,388,491.01. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Liquidia Stock Performance

LQDA opened at $27.38 on Friday. The business has a fifty day simple moving average of $65.76 and a 200-day simple moving average of $61.69. The firm has a market cap of $2.45 billion, a PE ratio of 19.99 and a beta of 0.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a fifty-two week low of $21.94 and a fifty-two week high of $93.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the previous year, the firm posted ($0.49) EPS. Liquidia’s quarterly revenue was up 1842.1% on a year-over-year basis. As a group, equities analysts predict that Liquidia Corporation will post 2.10 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new position in Liquidia during the second quarter worth about $29,694,000. Bank of America Corp DE grew its stake in shares of Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Capricorn Fund Managers Ltd bought a new stake in Liquidia in the first quarter valued at $9,337,000. T3 Companies LLC purchased a new stake in Liquidia in the fourth quarter worth about $6,084,000. Finally, Eversept Partners LP grew its stake in Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Jefferies Financial Group raised Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. BTIG Research downgraded Liquidia from a “buy” rating to a “neutral” rating in a research report on Thursday, October 1st. Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Needham & Company LLC lowered their price objective on shares of Liquidia from $110.00 to $72.00 and set a “buy” rating for the company in a research report on Thursday, October 1st. Finally, Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $83.69.

View Our Latest Analysis on Liquidia

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).